A quick LIMRA and LOMA survey of financial services companies found that 91% have a pandemic stress scenario in place. In addition, 71% have assessed and quantified the potential impact on their key business in the event of higher mortality.
Nothing attracts media attention quite like a potential cure for cancer. Researchers from Cardiff University, UK, recently published this paper detailing one possible method to beat cancer with far-reaching, all-purpose abilities. While it is currently just a laboratory experiment, the method they have outlined certainly has merit.
Identifying depression is critical to minimizing patient distress, but despite treatment advances, excess mortality persists, says RGA's Akhilesh Pandey. He discusses the disease process, treatment and prognosis, and underwriting implications in On the Risk, the Journal of the Academy of Life Underwriters.
As today’s medical and technological advances continue to be utilized and applied to Diabetes mellitus (DM), a newer and even more complex framework for the disease is emerging, which may help us further our understanding of it. RGA's Dr. Karneen Tam explores the most recent classification update and some of the newer thinking emerging about DM in Reinsurance News.
What will the life insurance/annuity sector be like in 2030? Resource turned to some seasoned executives for answers.
Brooks Tingle, president and chief executive officer, John Hancock Insurance, said the organization wants to promote engagement with insureds by partnering with a growing range of tech and service providers. Tingle spoke with AM BestTV at InsureTech Connect 2019, held in Las Vegas.
Top industry analysts discuss AI and the life insurance industry
Marfan’s syndrome is a systemic connective tissue disease that is inherited. It is characterized by abnormalities of the skeletal, cardiovascular and ocular systems predominantly.
Underwriting practices today are a world away from those commonplace 20 years ago, but the biggest evolution is yet to come.
